Back
Speaker illustration

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)

Member of:

European Society of Cardiology

Abhinav Sharma is an Assistant Professor at McGill University in the Department of Medicine, Division of Cardiology. He completed his medical school and internal medicine from McMaster University and his cardiology fellowship from the University of Alberta. He started his PhD in epidemiology with a thesis focusing on the intersection of diabetes and heart failure (defending summer/fall 2019). He went to Duke University to complete a cardiovascular research fellowship (05/2015-05/2017). Following this, he went to Stanford University and completed an advanced heart failure and cardiac transplantation fellowship (06/2017-05/2018). He continued as a Postgraduate Visiting Scholar at Stanford University in digital health (06/2018-01/2019). He is the recipient of the FRQ-S Chercheur-Boursier Clinicien award (Junior 1).

Presentations Articles

Speech analysis to detect acute decompensated heart failure

Event: ESC Congress 2024

Topic: Artificial Intelligence (Machine Learning, Deep Learning)

Session: Artificial intelligence unleashed on digital biomarkers: a new era in personalised cardiovascular healthcare

Access
Like
Thumbnail

Association of actigraphy endpoints and 6-minute walk distance in patients with heart failure: a pilot study from the Courtois Cardiovascular Signature Program

Event: Heart Failure 2024

Topic: Remote Patient Monitoring and Telehealth

Session: ePosters in e-Cardiology/digital health 3

Access
Like
Thumbnail

Usability and acceptance of wearable digital health technologies among patients with heart failure: UTILIZE-HF

Event: Heart Failure 2024

Topic: Remote Patient Monitoring and Telehealth

Session: e-Cardiology/digital health - remote patient monitoring and telehealth

Access
Like
Thumbnail

Amazon Alexa to screen for SARSCoV2 symptoms

Event: Heart Failure 2023

Topic: Remote Patient Monitoring and Telehealth

Session: Late breaking clinical trials: acute heart failure and patients' monitoring

Access
Like
Thumbnail

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 6

Access
Like
Thumbnail

Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Event: ESC Congress 2022

Topic: Secondary Prevention

Session: Optimal risk factor therapy in high risk patients

Access
Like
Thumbnail

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Event: ESC Congress 2021 - The Digital Experience

Topic: Comorbidities

Session: Congress committee e-posters choice in heart failure

Access
Like
Thumbnail

Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial

Event: Heart Failure 2021

Topic: Comorbidities

Session: ePoster session

Access
Like
Thumbnail

Biomarkers and risk scores as predictors of progression in the heart failure patient

Event: ESC Congress 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Can we trump advanced heart failure, once and for all? Intercontinental perspectives

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources